AOD 9604/MOTS-C
Ships fully reconstituted · no mixing, no powder, no bacteriostatic waterFat Burning + Metabolic Reset
Dual-action combo for targeted fat burning and cellular metabolic optimization.
Choose your supply
Extra 10% off your first order · use code WELCOME10 at checkout (stacks with the supply discount above).
Frequently paired with
What it supports
- Targeted fat reduction
- Improved insulin sensitivity
- Enhanced mitochondrial function
- Cellular metabolic reset
- No impact on blood sugar or IGF-1
- Exercise-mimetic effects
- Supports sustainable body composition
The details
- Administration
- Subcutaneous injection
- Format
- 3mg/mL (AOD 9604) + 5mg/mL (MOTS-C), 5mL vial
- Typical dosing
- Per provider guidance, subcutaneous injection
- Best for
- Fat loss, metabolic optimization, insulin sensitivity
- Pairs well with
- CJC-1295/Ipamorelin, Tesamorelin
- Mechanism
- AOD 9604 stimulates lipolysis and inhibits fat storage without hormonal side effects. MOTS-C activates AMPK pathways to improve insulin sensitivity, mitochondrial function, and metabolic flexibility. Together they attack fat from two angles: burning existing stores and improving how your body uses energy.
How it works
Signal
AOD 9604/MOTS-c is given as a subcutaneous injection on a provider-determined schedule.
Cellular response
AOD 9604 stimulates lipolysis and inhibits fat storage without hormonal side effects. MOTS-c activates AMPK pathways to improve insulin sensitivity, mitochondrial function, and metabolic flexibility. Together they attack fat from two angles — burning existing stores and improving how your body uses energy.
Outcome
Over the following weeks most people notice steadier energy and fewer afternoon crashes first (weeks 1–2), then early fat loss around the midsection with workouts feeling more productive (weeks 2–4), then measurable body-fat reduction and better endurance and recovery (weeks 4–8), with metabolic markers like glucose and triglycerides often improving by week 8+. Diabetic patients should monitor blood glucose with their provider.
Sources & references
AOD 9604 fat reduction in obese subjects
Heffernan MA et al. Obes Res. 2004;12(8):1246–1254.
View sourceMOTS-c regulates metabolic homeostasis
Lee C et al. Cell Metab. 2015;21(3):443–454.
View sourceMOTS-c and exercise-induced physical decline
Reynolds JC et al. Nat Commun. 2021;12:470.
View sourceMOTS-c metabolic regulation and exercise mimicry
Cell Metabolism, 2015
View sourceAOD-9604 lipolysis independent of GH receptor
Diabetes, Obesity and Metabolism, 2008
View sourceMitochondrial-derived peptides and insulin sensitivity
Diabetologia, 2019
View sourceCombination metabolic peptides in clinical practice
Journal of Translational Medicine, 2022
View source
Common questions
Important safety information
AOD 9604/MOTS-C is available by prescription only and is dispensed after a licensed provider reviews your medical screening and determines it is appropriate for you. Compounded medications are prepared by a licensed U.S. pharmacy and are not FDA-approved products. Tell your provider about your full medical history and any medications you take.
- • Generally well tolerated
- • Possible injection site reactions
- • Monitor blood glucose in diabetic patients
- • Requires licensed provider supervision